Arch Biopartners (FRA:8HA) Total Operating Expense: €1.48 Mil (TTM As of Mar. 2026)


FRA:8HA Arch Biopartners Inc FRA:8HA
8 GF Score
Price €0.50
! 4 Warning Signs
View Full Analysis

What is Arch Biopartners Total Operating Expense?

Arch Biopartners FRA:8HA -15.27% 8 Total Operating Expense is €1.48 Mil as of Mar. 2026. GuruFocus rates FRA:8HA with a GF Score™ of 8/100. The stock has 4 warning signs investors should review.

Arch Biopartners's Total Operating Expense for the three months ended in Mar. 2026 was €0.29 Mil. Arch Biopartners's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €1.48 Mil.

Arch Biopartners Total Operating Expense Related Terms

Arch Biopartners Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Arch Biopartners's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arch Biopartners Total Operating Expense Chart

Arch Biopartners Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.60 0.82 2.08 2.37 0.77

Arch Biopartners Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.34 0.14 0.13 0.92 0.29
FRA:8HA
8GF Score
Arch Biopartners Inc FRA:8HA
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arch Biopartners Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €1.48 Mil mean?
Arch Biopartners (FRA:8HA) has a Total Operating Expense of €1.48 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Arch Biopartners and its competitors.
Is Arch Biopartners' Total Operating Expense too high?
Arch Biopartners' current Total Operating Expense is €1.48 Mil. Overall, Arch Biopartners has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Arch Biopartners' Total Operating Expense compare to VRTX and REGN?
Arch Biopartners' Total Operating Expense of €1.48 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Arch Biopartners and its competitors. Arch Biopartners's current Total Operating Expense is €1.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arch Biopartners stock overvalued right now?
Arch Biopartners (FRA:8HA) has a current Total Operating Expense of €1.48 Mil. The current Total Operating Expense is €1.48 Mil. Arch Biopartners' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Arch Biopartners (FRA:8HA), the current Total Operating Expense is €1.48 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Arch Biopartners Business Description

Other Exchanges ACHFF:USAARCH:Canada
Address 545 King Street West, Toronto, ON, CAN, M5V 1M1
Arch Biopartners Inc is a developer of a therapeutic pipeline designed to address acute kidney injury (AKI) and chronic kidney disease (CKD) by targeting inflammation- and toxin-related kidney damage. The group offers mechanism-based treatments, enabling patients suffering from both acute and chronic kidney conditions to benefit from novel, targeted therapies that address unmet medical needs in kidney care.
8GF Score

Get the complete analysis for FRA:8HA

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.50
Price